CYC-126
Treatment-Resistant Depression (TRD)
Phase 1Active / Lead Candidate
Key Facts
Indication
Treatment-Resistant Depression (TRD)
Phase
Phase 1
Status
Active / Lead Candidate
Company
About Cyclerion Therapeutics
Cyclerion Therapeutics has strategically pivoted from its prior sGC focus to become a neuropsychiatric-focused company developing personalized, device-enabled therapeutics. Its lead candidate, CYC-126, targets treatment-resistant depression (TRD) by aiming to 'reset' dysregulated brainwave patterns, representing a convergence of pharmacotherapy and digital health. Under the leadership of CEO Regina Graul, PhD, and supported by a board with deep CNS and biotech expertise, the company is building a pipeline intended to transform care in areas of significant unmet medical need. Cyclerion is publicly traded (NASDAQ: CYCN) and has recently announced a definitive merger agreement with Korsana Biosciences.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DOT | Motif Neurotech | Pre-clinical |
| FMP374 | FundaMental Pharma | Preclinical |
| R-107 | Tasman Therapeutics | Phase 3 |
| GH001 | GH Research | Phase 2b/3 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 3 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |